Novavax (NVAX) Total Current Liabilities (2010 - 2026)

Novavax's Total Current Liabilities history runs 17 years deep, the most recent figure standing at $342.5 million for Q1 2026.

• In Q1 2026, Total Current Liabilities fell 18.88% year-over-year to $342.5 million; the TTM figure through Mar 2026 stood at $342.5 million (down 18.88% YoY), while the FY2025 annual figure was $460.0 million, down 60.16% from the prior year.
• Total Current Liabilities was $342.5 million for Q1 2026 at Novavax, down from $460.0 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $2.5 billion in Q4 2022 to a low of $342.5 million in Q1 2026.
• Historically, Total Current Liabilities has averaged $1.3 billion across 5 years, with a median of $1.2 billion in 2024.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities soared 87.08% in 2022, then tumbled 66.39% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $2.5 billion in 2022, then plunged by 33.53% to $1.6 billion in 2023, then retreated by 29.4% to $1.2 billion in 2024, then plunged by 60.16% to $460.0 million in 2025, then declined by 25.54% to $342.5 million in 2026.
• The last three Total Current Liabilities figures came in at $342.5 million (Q1 2026), $460.0 million (Q4 2025), and $429.9 million (Q3 2025), per Business Quant data.